Mink Therapeutics (INKT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 18, 2025, to be held virtually, with voting on key proposals including director elections, an option exchange, and auditor ratification.

• Notice and access rules are used for proxy materials, with options for electronic or printed delivery to shareholders.

• A one-for-ten reverse stock split was effected on January 28, 2025, and all share numbers reflect this adjustment.

Voting matters and shareholder proposals

• Shareholders will vote to elect Jennifer Buell and Ulf Wiinberg as Class I directors for three-year terms expiring in 2028.

• Proposal to approve a one-time option exchange for employees, executives, consultants, and directors, replacing underwater options with new options at current market value.

• Proposal to ratify KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of seven members divided into three classes, with annual elections for one class.

• All directors attended all board and committee meetings in 2024.

• Board committees include Audit and Finance, Compensation, Corporate Governance and Nominating, and an Affiliate Transactions Committee.

• Majority of directors are independent, and executive sessions of independent directors are held regularly.

• Code of Ethics and Securities Trading Policy updated in 2023, with annual board and committee self-evaluations.